- BeiGene (NASDAQ:BGNE) announces that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor.
- TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psoriasis and inflammatory bowel disease.
- The first-in-human Phase 1 trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of BGB-23339.
- The trial is expected to enroll up to 115 healthy volunteers in Australia and/or China.
- BeiGene’s internally developed, highly selective next-generation BTK inhibitor BRUKINSA (zanubrutinib) is currently being evaluated in a Phase 2 trial in patients with active proliferative lupus nephritis.